How a cloud-based SSU Solution with a SaaS-based platform manages the complexities of study activation.
Five considerations to help organizations make better planning and forecasting decisions in an environment with such strict parameters.
Submission of PADERs to the FDA is required during post-marketing drug safety surveillance. Instill confidence in your results and regulatory submissions by partnering with an experienced partner.
PV activities will continue to grow in volume and complexity. Trusting an experienced partner to help manage PV requirements can free your team to concentrate on patient efficacy outcomes.
How the use of tools can enable your objective of ensuring patient safety by having the right amount of material available with an appropriate investment in inventory cost.
With spiraling costs and increasing stakeholder demands, it’s critical that studies get off to the right start.
Discover insights from the experts at a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, about the first clinical efficacy study of GNbAC1, a promising new approach for the treatment of MS.
A video overview of the valuable content that can be accessed as a DIA NOW user.
Learn about the application of immunoaffinity LC-MS to regulated bioanalysis of biotherapeutics.
Patient engagement solutions to expedite study recruitment.
Clinical packaging, logistics and import/export considerations that should be taken into account when developing a clinical supply strategy in China, Singapore and Japan.
Don't let the complex logistics involved in the handling of clinical supplies in certain regions of the world put your patients at risk or jeopardize both the study budget and timeline.
Sponsors require an end-to-end service that can provide comparators on a global scale. We understand that this requires a full supply chain solution to manage a clinical trial.
Expertise in the blinding, packaging and global distribution of investigational products.
Offered as part of our complete supply chain solution, masking or blinding of clinical trial supplies removes investigator and patient bias and limits a potential placebo effect.